1024 related articles for article (PubMed ID: 17644538)
1. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
2. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
3. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment.
Briot K; Garnero P; Le Henanff A; Dougados M; Roux C
Ann Rheum Dis; 2005 Aug; 64(8):1137-40. PubMed ID: 15642695
[TBL] [Abstract][Full Text] [Related]
4. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
5. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A
Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456].
Forsblad d'Elia H; Christgau S; Mattsson LA; Saxne T; Ohlsson C; Nordborg E; Carlsten H
Arthritis Res Ther; 2004; 6(5):R457-68. PubMed ID: 15380045
[TBL] [Abstract][Full Text] [Related]
7. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
[TBL] [Abstract][Full Text] [Related]
8. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
[TBL] [Abstract][Full Text] [Related]
9. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
10. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
11. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.
Marotte H; Pallot-Prades B; Grange L; Gaudin P; Alexandre C; Miossec P
Arthritis Res Ther; 2007; 9(3):R61. PubMed ID: 17597527
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
13. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
14. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
[TBL] [Abstract][Full Text] [Related]
15. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
[TBL] [Abstract][Full Text] [Related]
16. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.
Güler-Yüksel M; Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Groenendael JH; Mallée C; de Bois MH; Breedveld FC; Dijkmans BA; Lems WF
Ann Rheum Dis; 2009 Mar; 68(3):330-6. PubMed ID: 18375540
[TBL] [Abstract][Full Text] [Related]
17. Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis.
Weitoft T; Larsson A; Saxne T; Rönnblom L
Ann Rheum Dis; 2005 Dec; 64(12):1750-3. PubMed ID: 15843449
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
[TBL] [Abstract][Full Text] [Related]
19. Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
Cremers SC; Lodder MC; Den Hartigh J; Vermeij P; Van Pelt P; Lems WF; Papapoulos SE; Dijkmans BA
J Rheumatol; 2004 Sep; 31(9):1732-7. PubMed ID: 15338492
[TBL] [Abstract][Full Text] [Related]
20. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
